Black Swan Analysis Epiomic Epidemiology Series Forecast Report on Chronic Heart Failure in 12 Major Markets
Chronic heart failure CHF is a chronic disease during which the heart is not able to supply sufficient blood flow to the body. Exacerbations of CHF are characterised by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs. The disease is associated with toxic, inflammatory and infective heart damage, structural, metabolic and genetic heart abnormalities, as well as cardiovascular risk factors, such as smoking, sedentary lifestyle, unhealthy diet and alcohol consumption.
This report provides the current prevalent population for chronic heart failure across 12 Major Markets USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, Brazil India split by gender and 5year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a valueadded level of insight from the analysis team at Black Swan, patient populations with the two types of chronic heart failure, as well as several of the main symptoms and comorbidities of chronic heart failure have been quantified and presented alongside the overall prevalence figures. These subpopulations within the main disease are also included at a country level across the 10year forecast snapshot.
Main symptoms and comorbidities for chronic heart failure include:
Arterial hypertension
Coronary artery disease
Atrial fibrillation
Diabetes mellitus
Metabolic syndrome
Obesity
Renal dysfunction
Chronic obstructive pulmonary disease COPD
Pulmonary hypertension
Sleep apnoea
Anaemia
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
Able to quantify patient populations in global chronic heart failure market to target the development of future products, pricing strategies and launch plans.
Gain further insight into the prevalence of the subdivided types of chronic heart failure and identify patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Provide a level of understanding on the impact from specific comorbid conditions on chronic heart failure's prevalent population.
Identify subpopulations within chronic heart failure which require treatment.
Gain an understanding of the specific markets that have the largest number of chronic heart failure patients.
Original Article: EPIOMIC EPIDEMIOLOGY SERIES: CHRONIC HEART FAILURE FORECAST IN 12 MAJOR MARKETS 20182028 [Report Updated: 01122017] Prices from USD $5000